Navigation Links
Tapestry Reports Second Quarter 2007 Results
Date:8/19/2007

Results Reflect Continued Investment in Clinical Development of TPI 287

BOULDER, Colo., Aug. 9 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH) announced today financial results for the second quarter ended June 27, 2007.

The net loss for the second quarter of 2007 was $6.2 million, or $0.37 per share. This compares to a net loss for the second quarter of 2006 of $4.2 million, or $0.28 per share. Included in the net loss for the second quarter of 2007 and 2006 is non-cash equity compensation expense totaling $893,000 and $1.3 million, respectively.

The net loss for the six-months ended June 27, 2007 was $10.6 million, or $0.64 per share. This compares to a net loss for the six-months ended June 28, 2006 of $8.6 million, or $0.92 per share. Included in the net loss for the six-months ended June 27, 2007 and June 28, 2006 is non-cash equity compensation expense totaling $1.7 million and $1.9 million, respectively.

As of June 27, 2007, Tapestry had $14.4 million in cash, cash equivalents, and short-term investments.

"The first half of 2007 has been an extremely exciting time at the company, as we initiated our first Phase 2 trial for TPI 287, in hormone refractory prostate cancer, and shared promising preclinical and Phase I clinical data at AACR and ASCO," commented Leonard Shaykin, Chairman and CEO. "We plan to build on this momentum in the second half of the year as we initiate our second and third Phase 2 trials in pancreatic cancer and in glioblastoma multiforme and our first oral Phase 1b/2 PK study in man. By early 2008, we expect to have preliminary results from the first arm of our Phase 2 trial in hormone refractory prostate cancer and begin an additional exploratory Phase 2 trial in yet another cancer indication."

Conference Call Information

Tapestry will host a conference call at 9:00 a.m. Eastern Time on August 9, 2007 to discuss 2007 second quarter results and recent corporate developments. To participate in the conference call, please dial 800-599-9795 (domestic) or 617-786-2905 (international) and reference the access code 29185656. A replay of the call will be available from 11:00 a.m. Eastern Time on August 9, 2007 until August 16, 2007 at midnight Eastern Time. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and reference the access code 85506220. A live audio webcast of the call will also be available on the "Investors" section of the Company's website, http://www.tapestrypharma.com. An archived webcast will be available on the Tapestry website for approximately 30 days after the event.

About Tapestry Pharmaceuticals, Inc.

Tapestry Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer.

For more information about Tapestry and its technologies, visit Tapestry's website at http://www.tapestrypharma.com.

About TPI 287

TPI 287, a proprietary next-generation taxane, is Tapestry's lead clinical compound. This compound was designed to overcome multiple drug resistance in solid tumors that are innately resistant to taxane therapy or have become resistant to taxanes following exposure to chemotherapy drugs. In preclinical testing, TPI 287 demonstrated the ability to inhibit tumor cell growth in a number of in vitro cell lines and has shown inhibition of human tumor growth in certain animal xenograft models when tested against standard comparative agents. The in vitro activity was seen across multiple cell lines including cell lines known to be sensitive to taxanes as well as cell lines known to be resistant to taxanes. Taxane sensitive cell lines in which TPI 287 has shown activity include cell lines derived from breast cancer, uterine cancer and non-small cell lung cancer. Taxane resistant cell lines in which TPI 287 has shown activity include cell lines derived from breast cancer, colon cancer and prostate cancer.

Forward-Looking Statements

Statements in this press release that are not historical facts are "forward-looking statements" that involve risks and uncertainties. Forward- looking statements can be identified by the use of words such as "opportunities," "trends," "potential," "estimates," "may," "will," "should," "anticipates," "expects," "hopes" or comparable terminology or by discussions of strategy. Such forward-looking statements include the statements that in the second half of 2007 the Company will initiate two additional Phase II trials of TPI 287 and initiate an oral Phase 1b/2 trial and that in the early part of 2008 the Company expects to have preliminary results in a Phase 2 trial and begin an exploratory Phase 2 trial in another cancer indication. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and manufacturing difficulties, delays in finalizing and receiving approval of protocols, negotiations with regulatory agencies, or other factors; that human clinical trials may show that TPI 287 is unsafe and/or ineffective in treating cancer in humans. General implementation risks associated with development of TPI 287 include those that we are blocked or limited in the development of TPI 287 because of the intellectual property rights of third parties; that we are limited in our ability to obtain, maintain and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; and that the Company's resources will be insufficient to continue development. Additional risks, uncertainties and other factors are identified under the captions "Risk Factors" and "Special Note Regarding Forward-Looking Statements" in the Company's reports filed from time to time with the Securities and Exchange Commission, including its Quarterly Reports on Form 10-Q for the periods ended March 28, 2007, and June 27, 2007. The Company cautions investors not to place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update publicly or revise any forward-looking statements, whether as a result of new or additional information, future events or otherwise.

Contact: Tapestry Pharmaceuticals, Inc.

Gordon Link

Senior Vice President, Chief Financial Officer

303-516-8500

glink@tapestrypharma.com

Investor: Lilian Stern

Stern Investor Relations, Inc.

212-362-1200

lilian@sternir.com

Media: Dana Conti

Schwartz Communications

781-684-0770

tapestry@schwartz-pr.com

Tapestry Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(In thousands)

June 27, December 27,

ASSETS 2007 2006

(unaudited)

Current assets:

Cash and cash equivalents $443 $180

Short-term investments 13,985 22,277

Prepaid expense and other current assets 489 335

Total current assets 14,917 22,792

Other assets 2,150 1,814

Total assets $17,067 $24,606

LIABILITIES AND STOCKHOLDERS' EQUITY

Total current liabilities $3,550 $2,585

Long-term debt, excluding current portion 53 112

Total stockholders' equity 13,464 21,909

Total liabilities and stockholders' equity $17,067 $24,606

Tapestry Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

Three-Months Ended Six-Months Ended

June 27, June 28, June 27, June 28,

2007 2006 2007 2006

Operating expenses:

Research and development $3,994 $2,391 $6,887 $5,205

General and administrative 2,398 2,038 4,175 3,495

Operating loss 6,392 4,429 11,062 8,700

Other income (expense):

Interest and other income 222 394 493 536

Interest and other expense (5) (128) (12) (302)

Loss from continuing operations (6,175) (4,163) (10,581) (8,466)

Loss from discontinued operations - - - (88)

Net loss $(6,175) $(4,163) $(10,581) $(8,554)

Basic and diluted loss per share

from continuing operations $(0.37) $(0.28) $(0.64) $(0.91)

Basic and diluted loss per share

from discontinued operations $- $- $- $(0.01)

Basic and diluted loss per share $(0.37) $(0.28) $(0.64) $(0.92)

Basic and diluted weighted average

shares outstanding 16,510 15,052 16,442 9,268


'/>"/>
SOURCE Tapestry Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
(Date:5/25/2016)... May 25, 2016  Zymo Research Corp. announced ... new reference materials that help researchers obtain the ... to analyses. The rapid growth of the study ... to have standard methods to improve the reproducibility ... inherently exist at every step of the measurement ...
(Date:5/25/2016)... , May 25, 2016  Granger Diagnostics today announced ... for wounds and infections. This test ensures discovery ... select viruses. The test requires only a simple swab ... David G. Bostwick , MD, Chief ... facilitate wound healing: "We are excited to make ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... which come courtesy of leaders in the nursing and health care industry. It also ... and associations—namely Abilene Christian University. , As the nursing industry is coming out ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports hinting at a ... to wait until March 2017 for an interest rate increase, according to Rajeev Dhawan ... Business. , “The Federal Open Market Committee (FOMC) dot charts are of interest to ...
(Date:5/26/2016)... California (PRWEB) , ... May 26, 2016 , ... ... associated with discovery of thousands of defective respirators, according to court documents and ... the case of William and Becky Tyler v. American Optical Corporation, Case No. ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to ... Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final ... and levels of the game, Connor Sports has committed to a significantly increased focus ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
Breaking Medicine News(10 mins):